Step­ping up be­hind Sanofi, Genen­tech rolls the DiCE on a new small mol­e­cule dis­cov­ery pact

Kevin Ju­dice al­ways made a point of stay­ing in touch with some the col­leagues he once worked with at Genen­tech, of­ten bring­ing them up to speed on the small mol­e­cule plat­form he was build­ing at DiCE Mol­e­cules. But he wasn’t quite ready to make any kind of a for­mal pitch on work­ing to­geth­er un­til one of the Bay Area gi­ant’s BD ex­ecs came call­ing re­cent­ly to get a clos­er look.

To­day, a lit­tle less than two years since DiCE Mol­e­cules lined up a $2.3 bil­lion dis­cov­ery pact with Sanofi, heav­i­ly weight­ed to biobucks, the lit­tle biotech has come back with its sec­ond big al­liance with Genen­tech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.